La cadena de opciones muestra datos clave de las opciones de acciones de Starbox Group Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Starbox Group Hldgs..

Starbox Group Hldgs (NASDAQ:STBX) Bolsa, Cadena de Opciones

Starbox Group Hldgs

Starbox Group Holdings Ltd engages in developing cash rebate, digital advertising, and payment solution business ecosystem targeting micro, small, and medium enterprises. Through the firm's subsidiaries in Malaysia, it connects retail merchants with retail shoppers to facilitate transactions through cash rebates offered by retail merchants, provide digital advertising services to advertisers, and provide payment solution services to merchants. Substantially all of its current operations are located in Malaysia. It operates in five segments include Cash rebate, payment solution, and media booking, Advertising services, Software licensing and Production services, Marketing and Promotional campaign services segment.

Starbox Group Holdings Ltd. - Class A Ordinary Shares

Starbox Group Holdings Ltd

Movers

Trading Ideas

CTCX

Carmell Corporation Shares Halted On Circuit Breaker

In the current market session, RPM Intl Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) share price is at $123.50, after a 0.36% spike. Moreover, over the past month, the stock fell by 11.21%, but in the past year, went up by 16.26%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1735828208_0.png" alt="Past Year Chart" />

<h3>RPM Intl P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 53.79 in the Chemicals industry, RPM Intl Inc. has a lower P/E ratio of 25.8. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1735828208_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

Price Over Earnings Overview: RPM Intl

Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) has outperformed the market over the past 15 years by 3.12% on an annualized basis producing an average annual return of 14.61%. Currently, Expedia Group has a market capitalization of $24.88 billion. 
Buying $1000 In EXPE: If an investor had bought $1000 of EXPE stock 15 years ago, it would be worth $7,663.87 today based on a price of $187.83 for EXPE at the time of writing.
<h3>Expedia Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735828208_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXPE

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) saw its shares rise on Thursday following the launch of the Lucid Assistant by Lucid Group, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).
This voice assistant offers Lucid Air owners a new way to control vehicle functions using only their voice, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42764010/soundhound-ai-and-lucid-motors-bring-in-vehicle-voice-assistant-with-integrated-generative-ai-to-e" rel="noreferrer noopener">according to a press release.</a>
The assistant responds to the wake words &#8220;Hey Lucid,&#8221; allowing drivers and passengers to engage in natural, conversational exchanges.
From answering real-time queries about weather, stocks, and sports, to controlling critical vehicle features like navigation, the Lucid Assistant offers an impressive range of capabilities.
Furthermore, it gives users access to the vehicle&#8217;s full manual, providing answers to almost any question about the car&#8217;s functionality.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/25/01/42757901/elon-musk-fireworks-or-explosive-device-caused-fatal-cybertruck-incident-at-las-vegas-trump-hotel-vehicle-was-rented" rel="noreferrer noopener">Elon Musk: Fireworks Or Explosive Device Caused Fatal Cybertruck Incident At Las Vegas Trump Hotel; Vehicle Was Rented</a>
The Lucid Assistant is powered by SoundHound&#8217;s advanced Chat AI, which integrates the latest generative AI technology, providing a seamless user experience with interactive knowledge discovery, real-time data, and intuitive in-vehicle controls.
SoundHound will showcase the Lucid Assistant at CES, where attendees can experience its functionality in the Lucid Air.
&#8220;Developing Lucid Assistant in cooperation with SoundHound enables us to deliver much more than a voice control feature,&#8221; said&nbsp;Jean-Philippe Gauthier, Head of Software Engineering at Lucid.
&#8220;In combination with Lucid&#8217;s frequent over-the-air software updates, Lucid Assistant can grow in functionality and capability over time, delivering an ever-better experience for Lucid owners.&#8221;
Lucid&#8217;s collaboration with SoundHound aims to create an evolving voice control experience that improves over time through regular software updates.
The system uses a proprietary approach, which minimizes the risk of &#8220;AI hallucinations&#8221;—misleading responses often associated with other large language models.
Currently available in English, Spanish, French, Arabic, German, and Dutch, the Lucid Assistant promises to enhance the driving experience and revolutionize how drivers interact with their vehicles.
Price Action: LCID shares are trading higher by 1.32% to $3.06 premarket at last check Thursday, while SOUN shares are trading higher by 2.92% to $20.42.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/12/42741855/elon-musks-ex-wife-and-mother-of-5-kids-says-he-wont-take-no-for-an-answer-he-locks-his-gaze-on-to-something-and-says-it-shall-be-mine?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk's Ex-Wife And Mother Of 5 Kids Says He Won't Take No For An Answer – He Locks His Gaze On To Something And Says, It Shall Be Mine</a></li>
</ul>
Photo via Shutterstock.

Equities

General

LCID

SOUN

'Hey Lucid': SoundHound AI Powers Next-Gen Voice Tech In Lucid Air

Deutsche Bank analyst Scott Deuschle maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Hold and lowers the price target from $250 to $229.

Price Target

Analyst Ratings

Deutsche Bank Maintains Hold on L3Harris Technologies, Lowers Price Target to $229

The new year brought little cheer for prospective U.S. homebuyers, as mortgage rates surged to their highest <a href="https://www.benzinga.com/real-estate">level in six months. </a>
The average interest rate on 30-year fixed-rate mortgages with conforming loan balances of $766,550 or less climbed to 6.97% in the week ending Dec. 27, 2024, up from 6.75% the previous week, according to data released Thursday by the Mortgage Bankers Association.
This marks the steepest rates since early July, as long-term Treasury yields remain elevated following the Federal Reserve's hawkish monetary stance. 
Notably, mortgage rates, which had trended lower for much of the first half of 2024, are now 21 basis points higher than this time last year, flipping the script on what had been a relatively friendly market for borrowers.
The surge in mortgage rates reflects broader shifts in financial markets, with long-dated Treasury yields rising alongside the Federal Open Market Committee's (FOMC) projections of fewer than-expected interest rate cuts.
<h3 class="wp-block-heading">Mortgage Applications Tumble 12.6%</h3>
With borrowing costs approaching the psychologically significant 7% threshold, mortgage activity took a nosedive. The MBA reported that mortgage applications fell 12.6% during the same week, compounding a 10.7% decline from the previous period. Seasonally adjusted, this leaves mortgage volumes at their lowest level in 10 months.
The sharp drop suggests that higher rates are squeezing demand, with many prospective buyers either unable or unwilling to lock in mortgages under such unfavorable conditions.
<h3 class="wp-block-heading">Labor Market Shows Resilience</h3>
On the flip side, labor market data offered a glimmer of optimism, as initial jobless claims fell to 211,000 in the week ending Dec. 28, down from 219,000 the previous week and beating market expectations of 222,000.
Continuing claims, which track those already receiving unemployment benefits, also dipped to 1.844 million, the lowest level since late September and below forecasts of 1.890 million. The steady decline in claims suggests that the U.S. job market remains robust in the face of rising borrowing costs.
<h3 class="wp-block-heading">Market Reactions</h3>
Thursday delivered a dose of optimism for markets as risk sentiment rebounded sharply ahead of the first trading session of the new year.
Following Tuesday&#8217;s selloff, major equity futures jumped in early trading. As of 8:40 a.m. ET, contracts on the S&amp;P 500 climbed 1%. Meanwhile, futures tied to the tech-heavy Nasdaq 100 jumped 1.2%. 
Meanwhile, the U.S. dollar index (DXY) — as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) — rose 0.3% to 108.80 levels, reaching the highest since November 2022.
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42761107/us-stocks-to-open-higher-in-the-first-trading-session-of-2025-analyst-says-history-favors-rebound-after-year-end-dip">US Stocks To Open Higher In The First Trading Session Of 2025: Analyst Says History Favors Rebound After Year-End Dip</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Currency ETFs

Economics

Federal Reserve

Tech

ETFs

PowerShares DB US Dollar Index Bullish Fund

Mortgage Rates Soar To 6.97%, Applications Crash, Jobless Claims Fall: Thursday's Economic Data

On Thursday, iBio, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NYSE">IBIO</a>) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc.
In March, iBio collaborated with&nbsp;AstralBio to discover, engineer, and develop antibodies to treat obesity and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37959621/micro-cap-stock-ibio-doubles-on-wednesday-heres-why" rel="noreferrer noopener">other cardiometabolic conditions</a>.
The antibody, now named IBIO-600, was identified by AstralBio using iBio&#8217;s proprietary technology stack. It was designed for subcutaneous administration and has the potential for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42761297/ibio-expands-cardiometabolic-and-obesity-program-with-anti-myostatin-antibody-discovered-using-its" rel="noreferrer noopener">an extended half-life</a>.
AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio.
In addition, AstralBio will be eligible for development and commercialization milestone payments totaling up to $28 million.
If iBio sublicenses the licensed product, AstralBio will receive low to mid-single-digit sublicense fees on the proceeds of the sublicense fees.
iBio is solely responsible for the research and development, manufacturing, and commercialization activities of the licensed product.
In parallel, iBio initiated a bispecific antibody program targeting myostatin/activin A to treat obesity and cardiometabolic disorders, leveraging its proprietary Drug Discovery Platform and the technology of IBIO-600.
The myostatin licensing agreement and planned myostatin/activin A bispecific antibody program follows a drug discovery and development collaboration between iBio and AstralBio initiated less than a year ago.
iBio plans to enter into clinical investigation in obesity and cardiometabolic disorders in 2026.
In preclinical studies, IBIO-600 exhibits potent inhibition of myostatin in human muscle cell precursors, effectively blocking its inhibitory effects on muscle growth.
The company adds that IBIO-600 has been engineered to bind to the FcRn receptor with more than 10-fold higher affinity than normal IgG, supporting the potential for reduced dosing frequency.
The molecule has been advanced into non-cGMP&nbsp;in vivo studies in rodents and non-human primates, with the first data read-outs expected in early 2025.
iBio plans to use the machine-learning and epitope-steering capabilities of the Stable HU antibody optimizer with advanced mammalian display to design and produce additional multispecific antibodies targeting TGF-beta superfamily, including Myostatin and Activin A in in-vitro studies.
Price Action: At last check on Thursday, IBIO stock was up 2.04% at $2.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42764490/us-employer-health-costs-to-rise-in-2025-fueled-by-weight-loss-report">US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Contracts

IBIO

Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

Reiteration

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

DA Davidson analyst Linda Bolton Weiser maintains Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) with a Buy and maintains $16 price target.

FNKO

DA Davidson Maintains Buy on Funko, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

SGMO

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

Deutsche Bank analyst Scott Deuschle maintains GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) with a Buy and lowers the price target from $235 to $228.

Deutsche Bank Maintains Buy on GE Aero, Lowers Price Target to $228

Eli Lilly and Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide) for market dominance.
According to a GlobalData <a target="_blank" href="https://www.globaldata.com/media/pharma/eli-lillys-zepbound-holds-potential-dominate-obesity-market-says-globaldata/" rel="noreferrer noopener">report</a>, Zepbound's superior effectiveness and strategic market growth position it to potentially overtake Wegovy as the <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">leading therapy for obesity</a>.
Since its debut, Zepbound has expanded its scope beyond obesity treatment. In December 2024, the FDA approved the drug for treating <a target="_blank" href="https://www.benzinga.com/general/health-care/24/12/42637278/eli-lillys-zepbound-receives-fda-approval-for-obesity-linked-sleep-apnea-drug" rel="noreferrer noopener">obstructive sleep apnea</a>.
Ongoing studies are exploring additional indications, such as reducing cardiovascular risks, addressing chronic kidney disease, and treating metabolic dysfunction-associated steatohepatitis (MASH).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a>.
GlobalData's Pharma Analyst, Costanza Alciati, highlighted that Eli Lilly is emulating Novo Nordisk's approach by exploring multiple therapeutic areas to broaden Zepbound's market potential.
Wegovy has been a game-changer in the obesity sector, earning widespread recognition and driving significant investment in the field. Over 400 companies are now developing obesity therapies inspired by Wegovy's success. The drug is also approved for managing type 2 diabetes and cardiovascular risks, with further research focusing on conditions like chronic kidney disease.
Despite Wegovy's achievements, Alciati remarked that Zepbound is "raising the bar" with greater potency and potential cost-effectiveness, making it a formidable contender in the obesity market.
In parallel, healthcare costs in the U.S. are climbing rapidly. Aon plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) August <a target="_blank" href="https://aon.mediaroom.com/2024-08-15-Aon-U-S-Employer-Health-Care-Costs-Projected-to-Increase-9-Percent-Next-Year" rel="noreferrer noopener">report</a> projects a 9% increase in employer-sponsored healthcare costs for 2025, exceeding $16,000 per employee.
This surge surpasses the 6.4% rise from 2023 to 2024, driven by higher medical claims, rising prescription drug expenses, and inflation-related adjustments.
Specialty drugs, particularly GLP-1 medications like tirzepatide and semaglutide, are key drivers of these rising costs. Aon's analysis reveals that these medications could add 1% to overall healthcare cost increases.
Despite their low utilization, these therapies significantly impact employer healthcare budgets.
On average, U.S. employers cover 81% of health plan costs, leaving employees to pay 19%, amounting to $4,858 annually, including premiums and out-of-pocket expenses.
In 2024, employer healthcare budgets grew by 6.4%, while employee premiums increased by a more modest 3.4%, according to Aon's analysis.
The technology and communications sector experienced the highest employer cost increase at 7.4% in 2024, while public sector employees faced the steepest rise in contributions at 6.7%.
In contrast, the healthcare industry saw no material change in employee contributions.
High-cost claims stemming from gene and cell therapies, complex medical procedures, and chronic conditions further strain employer budgets.
Price Action: LLY stock is up 0.88% at $778.79 during the premarket session at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/01/42763712/arcos-dorados-renews-franchise-agreement-with-mcdonalds-stock-gains" target="_blank" rel="noreferrer noopener">Arcos Dorados Renews Franchise Agreement With McDonald's, Stock Gains</a></li>
</ul>
Photo by Ciara Kimsey via Shutterstock

Large Cap

US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report

BWS Financial analyst Hamed Khorsand initiates coverage on Movado Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOV#NYSE">MOV</a>) with a Buy rating and announces Price Target of $31.5.

Initiation

BWS Financial Initiates Coverage On Movado Group with Buy Rating, Announces Price Target of $31.5

SPCB

SuperCom Announces Two Contracts With Agencies In Kentucky, Financial Details Not Disclosed

The tech world in 2025 is set to be defined by resilience, consolidation, and the unstoppable rise <a href="https://www.benzinga.com/topic/artificial-intelligence">of Edge AI</a>. 
JPMorgan analyst Samik Chatterjee has unveiled his top predictions for hardware and networking in 2025, and it's clear: the year will be all about resilience, edge AI, and a few surprising twists. Here's what investors need to know.
<h2 class="wp-block-heading">Apple, Edge AI: 2 Hot Tickets For 2025</h2>
Chatterjee is betting on Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to flex its muscles. He sees iPhone 17 hype and the rise of Edge AI keeping investors hooked. Forget the valuation debates—AI integration in smartphones and PCs could make Apple untouchable for much of the year.
While hyperscalers may grapple with AI scaling debates, Edge AI will steal the spotlight. By December, expect it to solidify as the darling of the tech world, powering smarter gadgets and keeping investors excited well into 2026.
AI's ROI remains focused on cost-cutting rather than driving revenue gains. Enterprises will stick to the basics, leveraging AI for leaner operations rather than headline-grabbing revenue boosts, the analyst said.
Read Also: <a href="https://www.benzinga.com/25/01/42758055/tim-cook-sundar-pichai-elon-musk-mark-zuckerberg-and-more-how-top-tech-ceos-ushered-in-2025-with-new-year-cheers-and-big-dreams">Tim Cook, Mark Zuckerberg, Elon Musk, And More: Tech Moguls Post Upbeat New Year Greetings: &#8216;Have A Good Feeling About 2025&#8217;</a>
<h2 class="wp-block-heading">Cloud Wars Favor Hardware</h2>
The long-running tug-of-war between on-premise and cloud infrastructure tilts toward hardware in 2025. According to Chatterjee, companies like Dell Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NASDAQ">DELL</a>) and Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) could shrug off fears of cloud dominance as enterprises reconsider the cloud's ROI for AI workloads.
<h2 class="wp-block-heading">AI Stocks: A Rollercoaster Ride</h2>
It won't be smooth sailing for AI-leveraged players like Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) and Coherent Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>), per Chatterjee. Early-year uncertainty will weigh on shares until mid-year earnings provide clarity. 
Investors will wait for the likes of Nvidia Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Blackwell and 800G Ethernet switching to gain traction.
<h2 class="wp-block-heading">Valuation Squeeze, Cyclicality To Spark M&amp;A Frenzy</h2>
Premium valuations across the hardware sector will narrow the gap between winners and laggards, says Chatterjee. The year's theme? Find value in the underdogs or wait for M&amp;A opportunities to unlock hidden potential.
As Telco, enterprise, and cable players gear up for a cyclical rebound, consolidation could heat up. Chatterjee predicts stronger players will snap up rivals to amplify recovery gains and slash costs.
<h2 class="wp-block-heading">Contract Manufacturers: The New Favorites</h2>
Historically overshadowed by OEMs, contract manufacturers are ready to shine. Lower risks, better margins, and ties to AI infrastructure projects could make them 2025's surprise winners.
<h2 class="wp-block-heading">Tariff Troubles Overblown</h2>
Worried about tariffs? Don't be. Chatterjee expects years of supply chain investments to shield companies from the worst, leaving doomsayers scratching their heads as stocks rise.
<h2 class="wp-block-heading">EV, AV: Hype Fatigue Sets In</h2>
Electric and autonomous vehicles will face another year of growing pains. With U.S. EV subsidies on shaky ground and slower progress in autonomous tech, optimism might fizzle—except for robotaxis, which could gain traction in tightly controlled spaces, says Chatterjee.
JPMorgan's vision for 2025 is clear: edge AI is the growth engine, Apple stays unstoppable, and consolidation could define the year. For investors, it's a roadmap to navigate the tech sector's next big moves.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/25/01/42759147/apple-discounts-iphone-16-prices-in-china-by-up-to-68-5-as-it-battles-huaweis-resurgence-in-the-country">Apple Discounts iPhone 16 Prices In China By Up To $68.5 As It Battles Huawei&#8217;s Resurgence In The Country</a></li>
</ul>
Photo: ImageFlow/ Shutterstock.com

Analyst Color

AAPL

ANET

COHR

CSCO

DELL

NVDA

Tech Predictions 2025: Apple's Edge AI Drive, M&A Heat, Cloud Hardware Shift

Deutsche Bank analyst Scott Deuschle maintains General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) with a Hold and lowers the price target from $303 to $295.

Deutsche Bank Maintains Hold on General Dynamics, Lowers Price Target to $295

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy-
-BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku-

CAPR

Capricor Therapeutics Completes Submission Of Biologics License Application To FDA for Deramiocel

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

N2OFF, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>) shares are trading higher premarket today. The clean-tech company has announced progress in its collaborative solar photovoltaic project in Melz, Germany, developed<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42762810/n2off-inc-announces-its-jv-with-soltera-renewable-energy-ltd-obtained-an-approval-of-111-mwp-solar" rel="noreferrer noopener"> alongside </a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42762810/n2off-inc-announces-its-jv-with-soltera-renewable-energy-ltd-obtained-an-approval-of-111-mwp-solar" rel="noreferrer noopener">Solterra Renewable Energy Ltd.</a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42762810/n2off-inc-announces-its-jv-with-soltera-renewable-energy-ltd-obtained-an-approval-of-111-mwp-solar" rel="noreferrer noopener"></a>
On December 31, 2024, the Melz municipal committee approved the submission of the statutory plan for the 111 MWp solar PV facility after a thorough review of environmental and planning considerations.
The approval marks a critical step toward achieving ready-to-build status, which is expected by the end of 2025.
The Melz project is N2OFF&#8217;s first venture into the renewable energy sector aimed at fostering the development of high-potential renewable energy projects across Europe.
The Melz facility is a development within Solterra&#8217;s broader portfolio, with a total capacity of approximately 300 MW across Germany, Italy, and Poland.
&#8220;This achievement reflects the strength of our collaboration with Solterra and our shared vision of delivering impactful solutions that promote clean energy and environmental sustainability,&#8221; said David Palach, CEO of N2OFF.
As part of its collaboration with Solterra, N2OFF has provided financial support, including an installment of 470,000 euros as part of a 2 million euro loan commitment.
Price Action: NITO shares are trading higher by 84% at $0.4562 in premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42761825/ev-price-war-heats-up-as-chinese-automakers-extend-subsidies" target="_blank" rel="noreferrer noopener">EV Price War Heats Up As Chinese Automakers Extend Subsidies: Details</a></li>
</ul>
Photo via Shutterstock.

WIIM

NITO

Why Is Clean Tech Company N2OFF Stock Soaring Premarket Thursday?

Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) has outperformed the market over the past 5 years by 15.57% on an annualized basis producing an average annual return of 28.24%. Currently, Pure Storage has a market capitalization of $20.31 billion. 
Buying $1000 In PSTG: If an investor had bought $1000 of PSTG stock 5 years ago, it would be worth $3,484.40 today based on a price of $62.26 for PSTG at the time of writing.
<h3>Pure Storage's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735827308_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PSTG

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has entered a software purchase agreement with Distributed I...

Starbox Group Secures Software Deal with Tech Firms

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has entered into a software purchase agreement involving its...

Starbox Group Boosts Tech Portfolio with Software Acquisition

19:50 EDT Starbox Group (STBX) Holdings Ltd trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...

Starbox Group Holdings Ltd trading halted, news pending

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has successfully completed the acquisition of an Immersive A...

Starbox Group Expands Digital Assets with Strategic Acquisition

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has successfully regained compliance with Nasdaq's minimum b...

Starbox Achieves Nasdaq Compliance, Secures Market Listing

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has entered into a software purchase agreement with Tech Fel...

Starbox Group Acquires Advanced 3D Software Framework

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has entered into a software purchase agreement alongside Fiv...

Starbox Group Facilitates Major Software Acquisition

16:53 EST Starbox Group (STBX) files to sell 20.85M Class A ordinary shares for holders Published first on TheFly – the ultimate source for real-ti...

Starbox Group files to sell 20.85M Class A ordinary shares for holders

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has successfully completed a share issuance and acquisition ...

Starbox Group Completes $9M Share Issuance and Acquisition

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has successfully completed the issuance of 6.1 million Class...

Starbox Group Expands with Strategic Software Acquisition

STBX

Earnings

Press Releases

Starbox Group Holdings Ltd. Announces Financial Results for Fiscal Year 2023

Starbox Launches AI-Driven Digital Human System for Merchants on WeChat Channels, Supporting Its Over 800 Merchants and Over Two Million Existing Users via Live Streaming and Short Videos

AI-Driven Digital Humans System Supporting Thousands of Merchants with Over 2 Million Users (Stock Symbol: STBX)

Starbox Launches "StarboxAI VI-Pro - Live Streaming System": Supporting Starbox's Merchants in Live Streaming Social Commerce

Powerful NASDAQ Listed AI Developer Launches StarboxAI VI-Pro – Live Streaming System; Empowering Over 800 of Merchants to Boost Sales to Over 2 Million Users: StarBox Group (Nasdaq: STBX)

Comments

Starbox Group Hldgs

Starbox Group Hldgs (STBX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL